跳至主要内容
临床试验/ISRCTN11242213
ISRCTN11242213已完成未知

The clinical and economic impact of the COVID-19 pandemic on people with obesity in Spain

ovo Nordisk Pharma S.A.0 个研究点目标入组 5,307 人开始时间: 2021年12月23日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
5,307

研究概览

简要总结

2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37342262/ (added 04/01/2024)

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Patients admitted to the HCSC in hospitalization regimen (primary care health care not included) between 01/03/2020-30/06/2020 with main and/or secondary diagnosis (ICD-10 codes): U07.1, U07.2, B34.2, B97.2, J12.81, J12.89, J12.90, J18.8, J18.9 or B97.29 + [J12.89, J12, J22, J40, J80, J98.8] and registered in the BDCLIN_HCSC_COVID-19 database
  • 2. Patients with COVID-19 microbiological diagnosis (positive PCR) and registered in the BDCLIN_HCSC_COVID-19 database from 01/03/2020 to 30/06/2020

排除标准

  • Does not meet inclusion criteria

研究者

发起方
ovo Nordisk Pharma S.A.

相似试验